Product image of Lantus (Insulin Glargine) supplied by GNH India

Lantus

Active Ingredient:
Insulin Glargine
Origin:
EU

Lantus (Insulin Glargine)

Insulin glargine, the active ingredient in Lantus, is a long‑acting insulin analog presented as a 100 U/mL injectable solution for subcutaneous administration. It provides basal insulin coverage and is indicated for the management of type 1 and type 2 diabetes mellitus in adult and pediatric patients.

GNH India supplies Lantus as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and logistics for this essential antidiabetic therapy and ensuring product integrity throughout the supply chain across multiple regions.

Manufacturer / TM Owner

Sanofi-Aventis Deutschland Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lantus (insulin glargine) is used to provide basal insulin in the management of diabetes mellitus.
  • Type 1 diabetes mellitus: maintains basal insulin levels to control fasting glucose.
  • Type 2 diabetes mellitus: provides steady basal insulin to improve glycemic control in patients requiring insulin therapy.
  • Adjunct therapy in insulin‑treated patients: complements rapid‑acting insulin to achieve overall glycemic targets.

How It Works

  • Insulin glargine binds to insulin receptors on peripheral tissues, activating the receptor’s tyrosine kinase activity. This triggers intracellular signaling cascades that promote glucose uptake in muscle and adipose tissue, inhibit hepatic gluconeogenesis, and facilitate glycogen synthesis, resulting in lowered blood glucose levels with a prolonged, peak‑less action profile.

Side Effects

Lantus may cause a range of adverse reactions.

Common Side Effects

  • Hypoglycemia, especially if meals are missed or dosing is excessive.
  • Injection‑site pain, redness, or swelling.
  • Weight gain due to improved glucose utilization.
  • Lipodystrophy at the injection site.
  • Mild allergic skin reactions.
  • Transient edema.

Serious or Rare Side Effects

  • Severe hypoglycemia leading to loss of consciousness.
  • Anaphylactic reactions or severe urticaria.
  • Persistent severe injection‑site necrosis.
  • Acute bronchospasm.
  • Hypersensitivity with systemic symptoms.
  • Unexplained rapid weight loss.

Precautions & Warnings

  • When using Lantus, consider the following safety measures.
  • Hypoglycemia risk: monitor blood glucose regularly and adjust dose as needed.
  • Renal or hepatic impairment: evaluate dose adjustments and monitor glucose trends.
  • Pregnancy: Category B; use only if benefits outweigh potential risks.
  • Elderly patients: initiate at lower doses and titrate cautiously.
  • Drug interactions: review concomitant medications that may affect glucose levels.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Lantus can interact with several drug classes.

Major Interactions (Avoid)

  • Concurrent sulfonylureas or meglitinides: increased risk of severe hypoglycemia.
  • Beta‑blockers: may mask hypoglycemia symptoms.
  • Alcohol: potentiates hypoglycemic effect.
  • MAO inhibitors: unpredictable glucose fluctuations.
  • High‑dose corticosteroids: may require dose escalation.

Moderate Interactions (Monitor Closely)

  • Thiazide diuretics: may raise blood glucose.
  • ACE inhibitors or ARBs: can enhance insulin sensitivity.
  • Oral contraceptives: may alter insulin requirements.
  • Lipid‑lowering agents (statins): monitor for rare hypersensitivity.
  • Antidepressants (SSRIs): observe for changes in glycemic control.

Frequently Asked Questions

Lantus is a brand of insulin glargine, a long‑acting insulin analog used to provide basal insulin coverage in patients with type 1 or type 2 diabetes mellitus. It helps maintain steady blood glucose levels between meals and overnight.

Insulin glargine binds to insulin receptors on muscle, fat, and liver cells, activating pathways that increase glucose uptake, reduce hepatic glucose production, and promote glycogen synthesis. Its altered molecular structure gives it a prolonged, peak‑less action lasting up to 24 hours.

The dose of Lantus is individualized. A qualified prescriber determines the starting amount and titration schedule based on the patient’s age, weight, type of diabetes, current glucose control, and other medical factors.

Insulin glargine is classified as Pregnancy Category B, indicating no evidence of risk in animal studies. It may be used in pregnancy or lactation when the potential benefit justifies the need, but the prescriber should evaluate each case.

To order Lantus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and any necessary import documentation.

Lantus (insulin glargine) offers a 24‑hour, peak‑less profile, similar to other long‑acting analogs such as insulin detemir or degludec. Compared with older NPH insulin, Lantus provides more predictable glucose control and a lower risk of nocturnal hypoglycemia.

Lantus should be stored in a refrigerator at 2‑8 °C. Keep the vial or pen in its original carton, protect it from light, and avoid freezing. Once in use, it may be kept at room temperature (up to 30 °C) for up to 28 days, but should not be exposed to extreme heat.

Lantus is administered by subcutaneous injection using a prefilled pen or vial and syringe. Injection sites include the abdomen, thigh, or upper arm. The dose is usually given once daily at the same time each day, but the exact schedule is set by the prescribing clinician.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated on recognizing early signs of low blood sugar and instructed to seek immediate medical attention for any severe reaction.

Lantus is contraindicated in individuals with a known hypersensitivity to insulin glargine or any of its excipients. It should also be avoided in patients with severe hypoglycemia unawareness unless closely monitored, and in those for whom a rapid‑acting insulin regimen is more appropriate.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Glargine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT